Skip to content
The Policy VaultThe Policy Vault

Rydapt (midostaurin capsules)Cigna

Myeloid or Lymphoid Neoplasms

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has eosinophilia
  • Patient meets ONE of the following (i or ii): (i) Patient has an FGFR1 rearrangement; OR (ii) Patient has an FLT3 rearrangement

Approval duration

1 year